Breaking News
Get 40% Off 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did 😎 Read how
Close

Glaukos Corp (GKOS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Glaukos Corp's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
108.74 +1.12    +1.04%
02:14:13 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 66,746
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 107.83 - 110.00
Type:  Equity
Market:  United States
Glaukos Corp 108.74 +1.12 +1.04%

Glaukos Corp Company Profile

 
Get an in-depth profile of Glaukos Corp, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

783

Equity Type

ORD

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Contact Information

Address One Glaukos Way
Aliso Viejo, 92656
United States
Phone 949 367 9600
Fax 949 367 9984

Top Executives

Name Age Since Title
Thomas W. Samuelson - - Member of Scientific Advisory Board
Richard L. Lindstrom 74 - Member of Scientific Advisory Board
Gilbert H. Kliman 63 2020 Independent Director
Ike K. Ahmed - - Member of Scientific Advisory Board
Kerry D. Solomon - - Member of Scientific Advisory Board
Richard A. Lewis - - Member of Scientific Advisory Board
Eric D. Donnenfeld 66 - Member of Scientific Advisory Board
Edward J. Holland - - Member of Scientific Advisory Board
Leana S. Wen 39 2021 Independent Director
Mark J. Foley 57 2014 Lead Independent Director
Denice M. Torres 62 2021 Independent Director
Kuldev Singh - - Member of Scientific Advisory Board
John Berdahl - - Member of Scientific Advisory Board
Robert J. Cionni - - Member of Scientific Advisory Board
Aimee S. Weisner 53 2014 Independent Director
Thomas William Burns 61 2002 Chairman & CEO
Marc A. Stapley 53 2014 Independent Director
David Frank Hoffmeister 68 2014 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GKOS Comments

Write your thoughts about Glaukos Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email